ArticleAME case reports2025
Pulmonary epithelioid hemangioendothelioma: a case report and review of literature.
Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelioid hemangioendothelioma (EHE) is a vascular tumor of unpredictable clinical behavior, representing a diagnostic and therapeutic challenge due to its rarity and complex presentation. This case report highlights a unique presentation of pulmonary EHE in a 69-year-old female and provides a comprehensive review of the literature to enhance awareness and understanding of this condition. Case Description: A 69-year-old Caucasian female with a history of type 2 diabetes and hypertension presented with progressive chest pain and right-sided neck and shoulder discomfort. Imaging revealed a significant right pleural effusion and a superior mediastinal mass, raising suspicion for malignancy. Histopathological analysis confirmed EHE, with immunohistochemical positivity for CD31 and negative staining for CD34, supporting the diagnosis. The patient underwent surgical resection and vascular stenting, followed by targeted therapy with trametinib as per SARC033 trial protocols. A 4-month follow-up showed no evidence of disease progression. Conclusions: The clinical ambiguity of EHE necessitates awareness and prompt action due to its potential for aggressive behavior and varied therapeutic responses. Early recognition, histopathological confirmation, and a multidisciplinary approach are essential for optimal management. While surgical resection is preferred for localized disease, targeted therapies show promise in advanced cases. Continued research is needed to refine treatment protocols and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.